Weekly radiotherapy for basal cell carcinoma in the frail and elderly

Abstract

gastrointestinal tract, thyroid, pituitary gland, liver and skin. Cutaneous adverse events include rash, pruritus, alopecia and vitiligo. A recent study including 1208 patients treated with ipilimumab showed an overall incidence of all-grade rash of 24Á3% 9 with no significant difference of frequency between melanoma and other malignancies, whereas pruritus may affect up to 31% of patients. 10 In the present case, we considered whether the TAD could be attributed to ipilimumab, based upon the following arguments: firstly, the absence of any other chronologically imputable treatment or any cause for abundant sweating; secondly, the complete resolution of the GD almost immediately after ipilimumab disruption, suggesting a direct, toxic (and not immunological) adverse effect and compatible with the ipilimumab half-life of 15 days. We assumed that this rapid clinical improvement was not imputable to the regression of the tumour because the metastatic disease progressed 2 months after the end of the treatment, although the GD did not relapse. Finally, the absence of exacerbation during the infusion period may be explained by the achievement of a stable plasmatic level at the time of the first infusion.To our knowledge, this is the first observation of TAD reported during ipilimumab treatment.

Efficacy of hypofractionated radiotherapy in patients with non‐melanoma skin cancer: Results of a systematic review

“…A thorough literature search (Fig. ) retrieved 40 relevant publications from 1983 to 2017 that fulfilled our inclusion criteria . Reported data pertaining to patient, tumour, RT and follow‐up are outlined in Table and .…”

“…In total, 12,337 irradiated lesions were accounted for across the 40 included publications . Thirty‐nine studies documented a mean of 272.2 patients per report . Twenty‐nine publications noted patient gender and a male predilection (54.5%) was demonstrated .…”

“…Twenty‐nine publications noted patient gender and a male predilection (54.5%) was demonstrated . Twenty‐nine studies recorded median (or mean) age which exceeded 70 years, in all but five reports . Weighted‐mean age was calculated to be 71.73 years from 15 publications and 4852 patients .…”

“…Twenty‐nine studies recorded median (or mean) age which exceeded 70 years, in all but five reports . Weighted‐mean age was calculated to be 71.73 years from 15 publications and 4852 patients . Median (or mean) tumour size ranged from 10 to 50 millimetres in thirteen studies .…”

“…Weighted‐mean age was calculated to be 71.73 years from 15 publications and 4852 patients . Median (or mean) tumour size ranged from 10 to 50 millimetres in thirteen studies . Twenty‐five publications acknowledged the lesions treated as either primary (92.6%) or recurrent (7.4%) disease .…”